AeroFact (AP-002)
/ Aerogen Pharma, Nuance Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
January 15, 2025
Safety and Efficacy of AeroFact in Preterm Infants With Respiratory Distress Syndrome
(clinicaltrials.gov)
- P3 | N=260 | Not yet recruiting | Sponsor: Aerogen Pharma Limited
New P3 trial • Acute Respiratory Distress Syndrome • Respiratory Diseases
August 06, 2024
A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact
(clinicaltrials.gov)
- P2 | N=261 | Completed | Sponsor: Aerogen Pharma Limited | Active, not recruiting ➔ Completed
Trial completion • Acute Respiratory Distress Syndrome • Respiratory Diseases
January 30, 2024
A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact
(clinicaltrials.gov)
- P2 | N=261 | Active, not recruiting | Sponsor: Aerogen Pharma Limited | Recruiting ➔ Active, not recruiting
Enrollment closed • Acute Respiratory Distress Syndrome • Respiratory Diseases
1 to 3
Of
3
Go to page
1